Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1. (original) Process for preparing a solid pharmaceutical composition of perindopril or a salt thereof, comprising

(i) dry mixing of perindopril or a salt thereof with at least one inorganic carbonate, at least one carrier, and optionally other components, and

(ii) dry processing of the mixture obtained in step (i) to the desired solid form.

2. (original) Process according to claim 1, wherein the composition comprises the tert.-butyl amine salt of perindopril.

3. (currently amended) Process according to claim 1 ~~or 2~~, wherein the inorganic carbonate is selected from the group consisting of sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate or calcium hydrogen carbonate.

4. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 3~~, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.

5. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 4~~, wherein the carrier is microcrystalline cellulose, lactose or a mixture thereof.

6. (original) Process according to claim 5, wherein the microcrystalline cellulose has a moisture content of 0.3 to 5.0% by weight, preferably 0.3 to 1.5% by weight.

7. (currently amended) Process according to claim 5 ~~or 6~~, wherein the lactose is anhydrous lactose.

8. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 7~~, wherein step (ii) is effected by direct compression of the mixture.

9. (currently amended) Process according to ~~any one of claims~~ claim 1 ~~to 8~~, wherein the composition also comprises indapamide or a hydrate thereof.

10. (original) Process according to claim 9, wherein the hydrate is indapamide hemihydrate.

11. (currently amended) Process according to claim 9 ~~or 10~~, wherein 90% of the particles of indapamide or a hydrate thereof have a size of less than 80 μm.

12. (original) Process according to claim 11, wherein 90% of the particles of indapamide or a hydrate thereof have a size of less than 70 μm.

13. (original) Solid pharmaceutical composition of perindopril or a salt thereof, comprising

(a) perindopril or a salt thereof,

(b) at least one of microcrystalline cellulose having a moisture content of 0.3 to 5.0% by weight and anhydrous lactose,

(c) optionally at least one inorganic carbonate, and

(d) optionally other components.

14. (original) Composition according to claim 13, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.

15. (currently amended) Composition according to claim 13 ~~or 14~~, wherein the microcrystalline cellulose has a moisture content of 0.3 to 1.5% by weight.

16. (original) Composition according to claim 15 which further comprises indapamide or a hydrate thereof.

17. (original) Composition according to claim 16, wherein 90% by volume of the particles of indapamide or a hydrate thereof have a size of less than 80 μm.